CDKN2A and meningioma: Additional TERT promoter mutation and homozygous CDKN2A/B loss have similarly been linked to more aggressive meningiomas In contrast, homozygous CDKN2A/B loss, TERT promoter mutations or alterations in BAP1 are associated with more aggressive clinical courses [1, 18, 33].